Home

RyCarma is developing first-in-class small molecule therapeutics for skeletal muscle diseases. RyCarma’s drug discovery platform is built from deep expertise on ryanodine receptors (RyRs), channels that regulate the intracellular flow of calcium ions in nearly all cell types. RyCarma’s RyR technology is based on the groundbreaking research by Columbia's Dr. Andrew Marks.

CNN visited Columbia University Fertility Center to see Dr. Zev Williams's red light therapy technology that improves the health of embryos.

TriGemX Bio, formerly known as Kallyope, is commercializing technology developed by Columbia's Dr. Charles Zuker, Dr. Tom Maniatis, and Dr. Richard Axel.